Substitutes for Bear Bile for the Treatment of Liver Diseases: Research Progress and Future Perspective

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2016 Apr 19

PMID 27087822

Citations 16

Authors

Sha Li

Hor Yue Tan

Ning Wang

Ming Hong

Lei Li

Fan Cheung

Yibin Feng

Affiliations

Soon will be listed here.

Abstract

Bear bile has been a well-known Chinese medicine for thousands of years. Because of the endangered species protection, the concept on substitutes for bear bile was proposed decades ago. Based on their chemical composition and pharmacologic actions, artificial bear bile, bile from other animals, synthetic compounds, and medicinal plants may be the promising candidates to replace bear bile for the similar therapeutic purpose. Accumulating research evidence has indicated that these potential substitutes for bear bile have displayed the same therapeutic effects as bear bile. However, stopping the use of bear bile is a challenging task. In this review, we extensively searched PubMed and CNKI for literatures, focusing on comparative studies between bear bile and its substitutes for the treatment of liver diseases. Recent research progress in potential substitutes for bear bile in the last decade is summarized, and a strategy for the use of substitutes for bear bile is discussed carefully.

Citing Articles

Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.

Bai S, Chandnani A, Cao S Biomedicines. 2025; 12(12).

PMID: 39767816 PMC: 11673883. DOI: 10.3390/biomedicines12122910.

TUDCA modulates drug bioavailability to regulate resistance to acute ER stress in .

Chadwick S, Stack-Couture S, Berg M, Di Gregorio S, Lung B, Genereaux J Mol Biol Cell. 2024; 36(2):ar13.

PMID: 39661468 PMC: 11809307. DOI: 10.1091/mbc.E24-04-0147.

The bile acid chenodeoxycholic acid associates with reduced stroke in humans and mice.

Monteiro-Cardoso V, Yeo X, Bae H, Mayan D, Wehbe M, Lee S J Lipid Res. 2024; 66(1):100712.

PMID: 39577772 PMC: 11721534. DOI: 10.1016/j.jlr.2024.100712.

Unveiling the gut-eye axis: how microbial metabolites influence ocular health and disease.

Nguyen Y, Rudd Zhong Manis J, Ronczkowski N, Bui T, Oxenrider A, Jadeja R Front Med (Lausanne). 2024; 11:1377186.

PMID: 38799150 PMC: 11122920. DOI: 10.3389/fmed.2024.1377186.

Neuroprotective Effect of Tauroursodeoxycholic Acid (TUDCA) on and Models of Retinal Disorders: A Systematic Review.

Li J, Huang Z, Jin Y, Liang L, Li Y, Xu K Curr Neuropharmacol. 2023; 22(8):1374-1390.

PMID: 37691227 PMC: 11092919. DOI: 10.2174/1570159X21666230907152207.

References

Pusl T, Vennegeerts T, Wimmer R, Denk G, Beuers U, Rust C . Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. Biochem Biophys Res Commun. 2008; 367(1):208-12. DOI: 10.1016/j.bbrc.2007.12.122. View

Cullen S, Rust C, Fleming K, Edwards C, Beuers U, Chapman R . High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008; 48(5):792-800. DOI: 10.1016/j.jhep.2007.12.023. View

Wimmer R, Hohenester S, Pusl T, Denk G, Rust C, Beuers U . Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. Gut. 2008; 57(10):1448-54. DOI: 10.1136/gut.2007.140871. View

Li Y, Zhu X, But P, Yeung H . Ethnopharmacology of bear gall bladder: I. J Ethnopharmacol. 1995; 47(1):27-31. DOI: 10.1016/0378-8741(95)01249-d. View

Watanabe S, Kamei T, Tanaka K, Kawasuji K, Yoshioka T, Ohno M . Roles of bile acid conjugates and phospholipids in in vitro activation of pancreatic lipase by bear bile and cattle bile. J Ethnopharmacol. 2009; 125(2):203-6. DOI: 10.1016/j.jep.2009.07.014. View

Wu S, Li L, Wang J . Ursodeoxycholic acid for nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2012; 24(11):1247-53. DOI: 10.1097/MEG.0b013e3283572ec0. View

Wang N, Feng Y, Zhu M, Tsang C, Man K, Tong Y . Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem. 2010; 111(6):1426-36. DOI: 10.1002/jcb.22869. View

Ikegami T, Matsuzaki Y . Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res. 2007; 38(2):123-31. DOI: 10.1111/j.1872-034X.2007.00297.x. View

Laukens D, Devisscher L, Van den Bossche L, Hindryckx P, Vandenbroucke R, Vandewynckel Y . Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. Lab Invest. 2014; 94(12):1419-30. DOI: 10.1038/labinvest.2014.117. View

10.

Zhao J, Liu L, Shen A, Lin W, Cao Z, Zhuang Q . [Effect of bear bile powder on STAT3 pathway in hepatocellular carcinoma xenograft]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014; 34(8):976-81. View

11.

Poupon R . Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol. 2012; 36 Suppl 1:S3-12. DOI: 10.1016/S2210-7401(12)70015-3. View

12.

Zhao J, Lin W, Zhuang Q, Zhong X, Peng J, Hong Z . Bear bile powder inhibits angiogenesis in vivo and in vitro. Chin J Integr Med. 2015; 21(5):369-75. DOI: 10.1007/s11655-015-2062-0. View

13.

Wang N, Feng Y, Cheung F, Chow O, Wang X, Su W . A comparative study on the hepatoprotective action of bear bile and Coptidis Rhizoma aqueous extract on experimental liver fibrosis in rats. BMC Complement Altern Med. 2012; 12:239. PMC: 3543725. DOI: 10.1186/1472-6882-12-239. View

14.

Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, Roda A . Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol. 2008; 2(2):155-77. DOI: 10.2174/157488407780598171. View

15.

Paumgartner G, Beuers U . Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002; 36(3):525-31. DOI: 10.1053/jhep.2002.36088. View

16.

Gu X, Li M, CHANG J, Cui G . [Comparison between pharmacologic actions of rabbit bile and bear bile]. Zhongguo Zhong Yao Za Zhi. 1994; 19(9):556-8, 575. View

17.

Liu L, Sakaguchi T, Cui X, Shirai Y, Nishimaki T, Hatakeyama K . Liver regeneration enhanced by orally administered ursodesoxycholic acid is mediated by immunosuppression in partially hepatectomized rats. Am J Chin Med. 2002; 30(1):119-26. DOI: 10.1142/S0192415X02000132. View

18.

Cho E, Yoon J, Kwak M, Jang E, Lee J, Yu S . Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet. Dig Dis Sci. 2014; 59(7):1461-74. DOI: 10.1007/s10620-014-3217-0. View

19.

Still J . Use of animal products in traditional Chinese medicine: environmental impact and health hazards. Complement Ther Med. 2003; 11(2):118-22. DOI: 10.1016/s0965-2299(03)00055-4. View

20.

Bi D, Chai X, Song Y, Lei Y, Tu P . Novel bile acids from bear bile powder and bile of geese. Chem Pharm Bull (Tokyo). 2009; 57(5):528-31. DOI: 10.1248/cpb.57.528. View